EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients

Fabrizio Pumo, Noriane Andrina Sievi, Thomas Gaisl, Carolin Steinack, Lasse Marck, René Hage, Silvia Ulrich, Macé Schuurmans, Maurice Roeder

Internal and Emergency Medicine · 2026-11 · 21 (8) · 2841-2850

DOI: 10.1007/s11739-026-04470-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Internal and Emergency Medicine, online erschienen am 24.07.2026. Verfasst von Fabrizio Pumo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. Hauptthemen laut MEDLINE: Ferric Compounds, Hypophosphatemia, Lung Transplantation, Maltose. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous ferric carboxymaltose ( FCM ) is frequently used to treat iron deficiency in lung transplant recipients ( LTRs ). Hypophosphatemia is a known adverse event after FCM administration, with reported significant hypophosphatemia following FCM administration in renal and heart transplant recipients. This study aimed to assess the incidence of hypophosphatemia after FCM administration and to identify potential risk factors in LTRs.

Methods

This retrospective, single-center study included LTRs treated with FCM during post-transplant follow-up between 2015 and 2022 at the University Hospital Zurich. Patients were included if serum phosphate was measured within six months before and after FCM infusion. Phosphate levels and clinical data were extracted from electronic records, and hypophosphatemia was classified by severity. Changes in phosphate levels over time were analyzed using mixed-effects models, and multivariable logistic regression was used to identify predictors of hypophosphatemia. Of note, phosphate measurements were obtained at routine follow-up visits, with the first post-infusion measurement occurring at a median of 32 days.

Results

Among 110 LTRs receiving FCM, 54.5% ( n = 60) developed hypophosphatemia (≤ 0.81 mmol/L). Mild, moderate, and severe hypophosphatemia occurred in 23.6% ( n = 26), 24.5% ( n = 27), and 6.4% ( n = 7) of patients, respectively. Use of 1000 mg FCM was associated with a higher risk of hypophosphatemia compared to 500 mg (OR (95% CI) of 2.54 (1.15–5.59)), increasing further after adjusting for baseline phosphate (OR (95% CI) of 5.18 (1.90–14.14)). Among patients with new-onset hypophosphatemia, 76% recovered within a median of 56 days. No serious clinical adverse events directly attributable to hypophosphatemia were documented.

Conclusions

Hypophosphatemia frequently occurred after FCM infusion in LTRs, particularly following higher doses. Transplant physicians should be mindful of this risk and consider using individualized FCM doses or alternative intravenous iron formulations with lower hypophosphatemia risk, such as ferric derisomaltose in this population. Trial registration www.ClinicalTrials.gov , NCT 06112236

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric CompoundsHypophosphatemiaLung TransplantationMaltoseAdultFemaleHumansMaleMiddle AgedAdministration, IntravenousIncidenceRetrospective StudiesRisk FactorsSwitzerland

Stichwörter der Autor:innen

AnemiaFCMHypophosphatemiaLung transplantation

Substanzen

ferric carboxymaltoseFerric CompoundsMaltose

Autor:innen und Institutionen

  • Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Department of Endocrinology, Hospital Wetzikon, Wetzikon, Switzerland.
  • Medical Faculty, University of Zurich, Zurich, Switzerland.
  • Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. m.roeder@lungenzentrum.ch.
  • LungenZentrum Hirslanden Zurich, Zurich, Switzerland. m.roeder@lungenzentrum.ch.

Förderung

  • University of Zurich

Zitieren

APA

Pumo, F., Sievi, N. A., Gaisl, T., Steinack, C., Marck, L., Hage, R., Ulrich, S., Schuurmans, M., & Roeder, M. (2026). Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients. Internal and Emergency Medicine, 21(8), 2841-2850. https://doi.org/10.1007/s11739-026-04470-3

Vancouver

Pumo F, Sievi NA, Gaisl T, Steinack C, Marck L, Hage R, et al. Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients. Internal and Emergency Medicine. 2026;21(8):2841-2850. doi:10.1007/s11739-026-04470-3

BibTeX
@article{Pumo2026,
  author = {Pumo, Fabrizio and Sievi, Noriane Andrina and Gaisl, Thomas and Steinack, Carolin and Marck, Lasse and Hage, René and Ulrich, Silvia and Schuurmans, Macé and Roeder, Maurice},
  title = {Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients},
  journal = {Internal and Emergency Medicine},
  year = {2026},
  volume = {21},
  number = {8},
  pages = {2841--2850},
  doi = {10.1007/s11739-026-04470-3}
}
Kostenlos starten →